Mylan (MYL) call equal at 1 to 1 amid new EpiPen criticism

August 24, 2016 2:15 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Mylan (NASDAQ: MYL) call equal at 1 to 1 amid new EpiPen criticism



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Add Your Comment